Pharmacogenomics: Current applications and future prospects towards personalized therapeutics

Journal of B.U.ON.

Volumn 18, Issue 3, 2013, Pages 570-578

  Vaiopoulou, A ^a   Gazouli, M ^a   Karikas, George Albert ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Cancer; Epigenetics; Personalized medicine; Pharmacogenomics; Polymorphisms

Indexed keywords

ANTILEUKEMIC AGENT; ATAZANAVIR; BETA LACTAM ANTIBIOTIC; CETUXIMAB; CLOPIDOGREL; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GLUTATHIONE TRANSFERASE; IMATINIB; INDINAVIR; MERCAPTOPURINE; METHOTREXATE; PANITUMUMAB; SIMVASTATIN; TAMOXIFEN; TRASTUZUMAB; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANALGESIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DRUG DISPOSITION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION; LUNG CANCER; METABOLOMICS; MYOPATHY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; THROMBOSIS; VIRUS INFECTION;

HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885753871     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Carlson CS, Eberle MA, Rieder MJ et al. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet 2003; 33: 518-521. (Pubitemid 36390016)
2. Hinds DA, Stuve LL, Nilsen GB et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307: 1072-1079. (Pubitemid 40262106)
3. Sachidanandam R, Weissman D, Schmidt SC et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928-933. (Pubitemid 32165347)
4. Magic Z, Supic G, Brankovic-Magic M. Towards targeted epigenetic therapy of cancer. J BUON 2009;14(Suppl 1):S79-88.
5. Cheok MH, Pottier N, Kager L et al. Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 39-51.
6. Sorich MJ, McKinnon RA. Personalized medicine: potential, barriers and contemporary issues. Curr Drug Metab 2012;13:1000-1006.
7. Cheng Q, Yang W, Raimondi SC et al. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005; 37: 878-882. (Pubitemid 41077115)
8. Hewitt P. Tufts Centre for the Study of Drug Development Pegs Cost of a New Prescription Medicine at $802 Million. Boston: Tufts Center for the Study of Drug Development, 2001.
9. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-185. (Pubitemid 36279392)
10. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002; 20: 1-10. (Pubitemid 35397394)
11. Evans W, Johnson JA. Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response. Annu Rev Genomics Hum Genet 2001; 2: 9-39. (Pubitemid 35264999)
12. Pirmohamed M, Breckenridge AM, Kitteringham NR et al. Adverse drug reactions. BMJ 1998; 316: 1295-1298.
13. Phillips KA, Veenstra DL, Oren EEO et al. Potential Role of Pharmacogenomics in reducing Adverse Drug Reactions: A Systematic Review. JAMA 2001; 286: 2270-2279. (Pubitemid 33063150)
14. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharmsci 2000; 2: E29.
15. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001; 14: 611-650. (Pubitemid 32565712)
16. Schlichting I, Berendzen J, Chu K et al. The catalytic pathway of cytochrome p450cam at atomic resolution. Science 2000; 287 (5458): 1615-1622. (Pubitemid 30127756)
17. Akagah B, Lormier AT, Fournet A, Figadère B. Oxidation of antiparasitic 2-substituted quinolines using metalloporphyrin catalysts: scale-up of a biomimetic reaction for metabolite production of drug candidates. Org Biomol Chem 2008; 6: 4494-4497.
18. Brazell C, Freeman A, Mosteller M. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance. Br J Clin Pharmacol 2002; 53: 224-231. (Pubitemid 34226964)
19. Kager L. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia. J BUON 2009; 14(Suppl 1):S181-186.
20. Evans W, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
21. Relling MV, Pui CH, Cheng C et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006; 107: 843-844. (Pubitemid 43076417)
22. Schwab M, Schäffeler E, Marx C et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-436. (Pubitemid 34918619)
23. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-614. (Pubitemid 27172187)
24. Evans WE, Horner M, Chu YQ et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase- deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119: 985-989.
25. Lennard L, Gibson BE, Nicole T et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69: 577-579. (Pubitemid 23355853)
26. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient Lancet 1993; 341: 1151. (Pubitemid 23125884)
27. Andersen JB, Szumlanski C, Weinshilboum RM et al. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998; 87: 108-111. (Pubitemid 28086619)
28. Schutz E, Gummert J, Mohr F et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341: 436. (Pubitemid 23048173)
29. Lennard L, Lilleyman JS, Van Loon J et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-229. (Pubitemid 20229068)
30. Drendel A. Pharmacogenomics of Analgesic Agents. Clin Ped Emerg Med 2007; 8: 262-267. (Pubitemid 350163027)
31. Stamer UM, Stüber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007;8:2235-2245. (Pubitemid 350001587)
32. Lötsch J, Rohrbacher M, Schmidt H et al. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 2009; 144: 119-124.
33. Kirchheiner J, Schmidt H, Tzvetkov M et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7: 257-265. (Pubitemid 47202488)
34. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429-444. (Pubitemid 46364493)
35. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293. (Pubitemid 40740552)
36. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478. (Pubitemid 30183327)
37. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-799.
38. Treviño LR, Shimasaki N, Yang W et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27: 5972-5978.
39. Ni W, Ji J, Dai Z et al. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS ONE 2010; 5: e13792.
40. Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
41. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 1022-1027.
42. Yang JJ, Cheng C, Yang W et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301: 393-403.
43. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics 2009; 10: 1323-1339.
44. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002; 1: 259-266. (Pubitemid 37361442)
45. Guéant-Rodriguez RM, Guéant JL, Viola M et al. Association of tumor necrosis factor-alpha -308G>A polymorphism with IgE-mediated allergy to beta lactams in an Italian population. Pharmacogenomics J 2008; 8: 162-168. (Pubitemid 351418952)
46. Trosko JE. The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy. Biomed Pharmacother 2005; 59: 326-331.
47. Karikas GA. Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J BUON 2010; 15: 627-638.
48. Karikas GA. Chemoprevention molecular and biochemical mechanisms involved in cancer control and management. Health Sci J 2011; 5: 149-156.
49. Karikas GA. Natural and synthetic agents in cancer chemoprevention. Pharmakeftiki 2012; 24:79-88.
50. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8: 1409-1420.
51. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-298. (Pubitemid 46439286)
52. Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
53. Dang W, Steffen KK, Perry R et al. Histone H4 lysine16 acetylation regulates cellular lifespan. Nature 2009; 459: 802-807.
54. Saito Y, Liang G, Egger G et al. Specific activation of microRNA-127 with down regulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-443. (Pubitemid 43832188)
55. Lujambio A, Ropero S, Ballestar E et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 1424-1429. (Pubitemid 46383366)
56. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-3995.
57. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
58. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792. (Pubitemid 40271173)
59. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655. (Pubitemid 40812628)
60. Growney JD, Clark JJ, Adelsperger J et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106:721-724. (Pubitemid 40981272)
61. Siehl J, Thiel E. C-kit, GIST, and imatinib. Recent Resuits Cancer Res 2007; 176: 145-151.
62. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 Mutation and Response to Trastuzumab Therapy in Non-Small-Cell Lung Cancer. N Engl J Med 2006; 354: 2619-2621. (Pubitemid 43882374)
63. Wong ALA, Lee SC. Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer 2012; 415170. doi: 10.1155/2012/415170. Epub 2012, May 9.
64. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
65. Arribas J, Baselga J, Pedersen K et al. p95HER2 and breast cancer. Cancer Res 2011; 71: 1515-1519.
66. Jain KK. Recent advances in clinical oncoproteomics. J BUON 2007;12(Suppl 1):S31-38. (Pubitemid 350200859)
67. Robertson JA, Brody B, Buchanan A et al. Pharmacogenetic Challenges For The Health Care system. Health Affairs 2002; 21: 155-167.
68. Stanek EJ, Sanders CL, Taber KA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012; 91: 450-458.
69. Shields AE, Lerman C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin Pharmacol Ther 2008; 83: 635-639. (Pubitemid 351417077)
70. McCullough KB, Formea CM, Berg KD et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ 2011; 75: 51.
71. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464-467.
72. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205. (Pubitemid 28193431)
73. Wong WB, Carlson JJ, Thariani R et al. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010; 28: 1001-1013.
74. van den Akker-van Marle ME, Gurwitz D, Detmar SB et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7: 783-792. (Pubitemid 44225913)
75. Hughes AR, Spreen WR, Mosteller M et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 2008; 8: 365-374.
76. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804-2812.